Diabetes drug semaglutide studied for lung clot recovery
NCT ID NCT06118203
First seen Apr 02, 2026 · Last updated Jun 23, 2026 · Updated 14 times
Summary
This completed study tested whether semaglutide, a drug used for diabetes, could reduce inflammation in 18 people who had a blood clot in their lungs (pulmonary embolism). Researchers measured changes in blood markers of inflammation over 4 weeks. The goal was to see if the drug might help recovery, but the study was small and focused on lab results, not patient symptoms.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY EMBOLISM are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Colm McCabe
London, SW3 6NP, United Kingdom
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Semaglutide
What this could lead to
If this works, it could point toward a new way to reduce inflammation after a pulmonary embolism.
What could go wrong
This is a very small, early study that only measured blood markers, not patient outcomes. The results may not lead to any treatment change.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.